From Yahoo Finance: 2025-04-29 07:06:00

Biohaven secures up to $600m in non-dilutive capital from Oberland Capital Management for potential US launch of troriluzole for SCA. First tranche of $250m to be funded by 30 April, with additional tranches contingent on FDA approval of troriluzole. Shares in Biohaven close 9.6% higher at $21.74 on 28 April.

Troriluzole, a prodrug of riluzole, is being evaluated for SCA with FDA priority review expected in Q3 2025. Biohaven positioning funding to accelerate commercial planning and advance CNS-targeting therapies. If approved, troriluzole would be Biohaven’s first greenlit product since spinning out from Pfizer in 2022.

Troriluzole faced setbacks in Phase III trial but showed benefits in certain subset of disease. FDA initially refused review but accepted revised submission. European Medicines Agency questions drug’s efficacy and classification as new active substance. Biohaven to generate additional data for EMA submission.

Biohaven formed new entity post-migraine asset divestiture to Pfizer in 2022, including Nurtec ODT. Pfizer settled allegations of kickbacks related to former Biohaven entity for $59.7m in January 2025. Story originally published by Pharmaceutical Technology.



Read more at Yahoo Finance: Biohaven secures $600m financing as it awaits FDA prodrug decision